目的 探讨脂必泰胶囊联合普罗布考治疗高脂血症的临床疗效。方法 选择2020年10月—2021年10月天津市南开医院收治的80例高脂血症患者，随机分对照组（40例）和治疗组（40例）。对照组患者口服普罗布考片，0.5 g/次，2次/d。在对照组的基础上，治疗组口服脂必泰胶囊，1粒/次，2次/d。两组患者治疗8周。观察两组患者临床疗效，比较治疗前后两组患者症状好转时间，血脂低密度脂蛋白胆固醇（LDL-C）、总胆固醇（TC）、三酰甘油（TG）和高密度脂蛋白胆固醇（HDL-C）水平，血清因子白细胞介素-6（IL-6）、血清单核细胞趋化蛋白-1（MCP-1）、细胞间黏附分子-1（ICAM-1）和肿瘤坏死因子-α（TNF-α）水平，及不良反应情况。结果 治疗后，治疗组临床有效率（97.50%）明显高于对照组（77.50%，P＜0.05）。治疗后，治疗组症状好转时间明显短于对照组（P＜0.05）。治疗后，两组TC、TG、LDL-C水平明显降低，而HDL-C水平明显升高（P＜0.05），且治疗组血脂水平明显好于对照组（P＜0.05）。治疗后，两组血清因子IL-6、MCP-1、TNF-α、ICAM-1水平明显低于治疗前（P＜0.05），且治疗组明显低于对照组（P＜0.05）。治疗组不良反应发生率（7.50%）明显低于对照组（17.50%，P＜0.05）。结论 脂必泰胶囊联合普罗布考治疗高脂血症效果良好，能有效改善血脂水平，并可减轻炎性反应，且安全有效。

Objective To investigate the clinical effect of Zhibitai Capsules combined with probucol in treatment of hyperlipidemia. Methods Patients (80 cases) with hyperlipidemia in Tianjin NanKai Hospital from October 2020 to October 2021 randomly were divided into control (40 cases) and treatment (40 cases) group. Patients in the control group was po administered with Probucol Tablets, 0.5 g/time, twice daily. Patients in the treatment group were po administered with Zhibitai Capsules on the basis of the control group, 1 grains/time, twice daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical evaluation was evaluated, and the improvement time of symptom, the levels of blood lipid TC, TG, LDL-C and HDL-C, the levels of serum IL-6, MCP-1, TNF-α and ICAM-1, and adverse reaction in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group (97.50%) was significantly higher than that of the control group (77.50%, P < 0.05). After treatment, the improvement time of symptom in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the levels of TC, TG and LDL-C were significantly decreased, while the level of HDL-C were significantly increased in two groups (P < 0.05), and the level of blood lipid in the treatment group was significantly better than that in the control group (P < 0.05). After treatment, the serum levels of IL-6, MCP-1, TNF-α and ICAM-1 in two groups were significantly lower than those before treatment (P < 0.05), which in the treatment group was significantly lower than that in the control group (P < 0.05). The incidence of adverse reactions in the treatment group (7.50%) was significantly lower than that in the control group (17.50%, P < 0.05). Conclusion Zhibitai Capsules combined with probucol is effective in the treatment of hyperlipidemia, which can effectively improve the level of blood lipids, and can reduce inflammatory reaction, and safe and effective.

R972